Critical Review: ProQR Therapeutics (NASDAQ:PRQR) & Cytek Biosciences (NASDAQ:CTKB)

ProQR Therapeutics (NASDAQ:PRQR) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Risk and Volatility

ProQR Therapeutics has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Valuation & Earnings

This table compares ProQR Therapeutics and Cytek Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99 million	8.96	-$47.73 million	($0.50)	-3.06
Cytek Biosciences	$201.49 million	2.78	-$66.54 million	($0.57)	-7.60

ProQR Therapeutics has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Cytek Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Analyst Recommendations

This is a breakdown of recent recommendations for ProQR Therapeutics and Cytek Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1	1	6	0	2.63
Cytek Biosciences	1	2	3	0	2.33

ProQR Therapeutics presently has a consensus target price of $7.25, indicating a potential upside of 373.86%. Cytek Biosciences has a consensus target price of $5.69, indicating a potential upside of 31.35%. Given ProQR Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Cytek Biosciences.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

About Cytek Biosciences

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.